Trial intelligence / Profile preview

First-in-human phase I/II study of STX-241 in EGFR TKI-resistant advanced or metastatic NSCLC

CTR20252260Phase 2Active

Sponsor

Pierre Fabre Laboratories

Start

Sep 2025

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1